David Liu
Fondateur chez Pairwise Plants Services
Fortune : 87 M $ au 30/04/2024
Profil
David R.
Liu is the founder of Ensemble Therapeutics Corp.
(2004), Permeon Biologics, Inc. (2008), and Editas Medicine, Inc. (2013).
Dr. Liu's current jobs are as a Professor at Harvard University and an Associate Member at Massachusetts Institute of Technology.
Dr. Liu's education history includes an undergraduate degree from Harvard University and a doctorate from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PRIME MEDICINE, INC.
16,81% | 31/03/2024 | 20 156 945 ( 16,81% ) | 87 M $ | 30/04/2024 |
Postes actifs de David Liu
| Sociétés | Poste | Début |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 06/09/2011 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | 06/09/2011 |
Pairwise Plants Services
 Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Pairwise Plants LLC operates as a agriculture company. The company was founded by Feng Zhang, David Liu and J. Keith Joung and is headquartered in Durham, NC. | Fondateur | - |
Anciens postes connus de David Liu
| Sociétés | Poste | Fin |
|---|---|---|
| PRIME MEDICINE, INC. | Fondateur | - |
Exo Therapeutics, Inc.
 Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Fondateur | - |
Ensemble Therapeutics Corp.
 Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA. | Fondateur | - |
| EDITAS MEDICINE, INC. | Fondateur | - |
Permeon Biologics, Inc.
 Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Fondateur | - |
Formation de David Liu
| Harvard University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EDITAS MEDICINE, INC. | Health Technology |
| PRIME MEDICINE, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Permeon Biologics, Inc.
Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Ensemble Therapeutics Corp.
Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA. | Process Industries |
Pairwise Plants Services
Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Pairwise Plants LLC operates as a agriculture company. The company was founded by Feng Zhang, David Liu and J. Keith Joung and is headquartered in Durham, NC. | Consumer Non-Durables |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Health Technology |